Gender differences in colon cancer treatment

Journal of Women's Health

Volumn 22, Issue 4, 2013, Pages 344-351

  Oliver, Joann S ^a   Martin, Michelle Y ^b   Richardson, Lisa ^c   Kim, Young ^b   Pisu, Maria ^b  

^a UNIVERSITY OF ALABAMA   (United States)

^b University of Alabama at Birmingham   (United States)

^c NATIONAL CENTER FOR CHRONIC DISEASE PREVENTION AND HEALTH PROMOTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FLUOROURACIL;

AGED; ANEMIA; ARTICLE; CANCER ADJUVANT THERAPY; CANCER REGISTRY; CANCER STAGING; CANCER SURGERY; CANCER THERAPY; COLON CANCER; DEHYDRATION; DIARRHEA; DRUG FEVER; ELECTROLYTE DISTURBANCE; FEMALE; HUMAN; INFECTION; MAJOR CLINICAL STUDY; MALE; MALNUTRITION; MEDICARE; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; SEPSIS; SEX DIFFERENCE; SOCIAL STATUS; THROMBOCYTOPENIA; TREATMENT DURATION; VOMITING;

ADOLESCENT; ADULT; AGE FACTORS; CARDIOVASCULAR DISEASES; FEMALE; HEALTH SERVICES ACCESSIBILITY; HUMANS; MASS SCREENING; NORTH CAROLINA; POVERTY AREAS; PREGNANCY; REPRODUCTIVE HEALTH; RISK FACTORS;

EID: 84876227917     PISSN: 15409996     EISSN: 1931843X     Source Type: Journal    
DOI: 10.1089/jwh.2012.3988     Document Type: Article

References (44)

1. American Cancer Society. Cancer Facts and Figures, 2012. Atlanta, GA: American Cancer Society, 2012.
2. Palmer RC, Schneider EC Social disparities across the con-tinuum of colorectal cancer: a systematic review. Cancer Causes Control 2005;16:55-61.
3. Hendifar A, Yang D, Lenz F, et al. Gender disparities in metastatic colorectal cancer survival. Clin Cancer Res 2009; 15:6391-6397.
4. Simon MS, Thomson CA, Pettijohn E, et al. Racial differences in colorectal cancer incidence and mortality in the Women's Health Initiative. Cancer Epidemiol Biomarkers Prev 2011; 20:1368-1378.
5. Soneji S, Iyer SS, Armstrong K, Asch DA. Racial disparities in stage-specific colorectal cancer mortality: 1960-2005. Am J Public Health 2010;100:1912-1916.
6. National Comprehensive Cancer Network (NCCN). Colon Cancer NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) 2012. http://www.nccn.org/ Accessed May 14, 2012.
7. National Cancer Institute. Colon Cancer Treatment (PDQ®). PDQ® - NCI's Comprehensive Cancer Database. http:// www.cancer.gov/cancertopics/pdq/ treatment/colon/Health Professional Accessed May 14, 2012.
8. Gill S, Loprinzi CL, Sargent DJ, et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much? J Clin Oncol 2004; 22:1797-1806.
9. Moertel CG, Fleming TR, Macdonald JS, et al. Levamisole and fluorouracil for adjuvant therapy of resected colon car-cinoma. N Engl J Med 1990;322:352-358.
10. Dimou A, Syrigos KN, Saif MW. Disparities in colorectal cancer in African-Americans vs whites: before and after di-agnosis. World J Gastroenterol 2009;15:3734-3743.
11. Neugut AI, Matasar M, Wang X, et al. Duration of adjuvant chemotherapy for colon cancer and survival among the el-derly. J Clin Oncol 2006;24:2368-2375.
12. Hofmann LJ, Lee S, Waddell B, Davis KG Effect of race on colon cancer treatment and outcomes in the Department of Defense healthcare system. Dis Colon Rectum 2010;53:9-15.
13. Chagpar R, Xing Y, Chiang YJ, et al. Adherence to stage-specific treatment guidelines for patients with colon cancer. J Clin Oncol 2012;30:972-979.
14. Schrag D, Cramer LD, Bach PB, Begg CB. Age and adjuvant chemotherapy use after surgery for stage III colon cancer. J Natl Cancer Inst 2001;93:850-857
15. Dobie SA, Baldwin LM, Dominitz JA, Matthews B, Bill-ingsley K, Barlow W. Completion of therapy by Medicare patients with stage III colon cancer. J Natl Cancer Inst 2006; 98:610-619.
16. Paulson EC, Wirtalla C, Armstrong K, Mahmoud NN. Gender influences treatment and survival in colorectal can-cer surgery. Dis Colon Rectum 2009;52:1982-1991.
17. Thoburn KK, German RR, Lewis M, Nichols PJ, Ahmed F, Jackson-Thompson J. Case completeness and data accu-racy in the Centers for Disease Control and Prevention's National Program of Cancer Registries. Cancer 2007;109: 1607-1616.
18. Tucker T, Howe H. Measuring the quality of population-based cancer registries: the NAACCR perspective. Journal of Registry Management 2001;28:41-44.
19. Hassett MJ, O'Malley AJ, Pakes JR, Newhouse JP, Earle CC. Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer. J Natl Cancer Inst 2006;98:1108-1117
20. Cen P, Liu C, Du XL. Comparison of toxicity profiles of fluorouracil versus oxaliplatin regimens in a large population-based cohort of elderly patients with colorectal cancer. Ann Oncol 2012;23:1503-1511.
21. Blackman SB, Lash TL, Fink AK, Ganz PA, Silliman RA. Advanced age and adjuvant tamoxifen prescription in early-stage breast carcinoma patients. Cancer 2002;95:2465-2472.
22. Dranitsaris G, Rayson D, Vincent M, et al. Identifying pa-tients at high risk for neutropenic complications during chemotherapy for metastatic breast cancer with doxorubicin or pegylated liposomal doxorubicin: the development of a prediction model. Am J Clin Oncol 2008;31:369-374.
23. Dranitsaris G, Rayson D, Vincent M, et al. The development of a predictive model to estimate cardiotoxic risk for patients with metastatic breast cancer receiving anthracyclines. Breast Cancer Res Treat 2008;107:443-450.
24. Echeverria SE, Borrell LN, Brown D, Rhoads G A local area analysis of racial, ethnic, and neighborhood disparities in breast cancer staging. Cancer Epidemiol Biomarkers Prev 2009;18:3024-3029.
25. Eheman CR, Berkowitz Z, Lee J, et al. Information-seeking styles among cancer patients before and after treatment by demographics and use of information sources. J Health Commun 2009;14:487-502.
26. Hershman DL, Buono D, McBride RB, et al. Surgeon char-acteristics and receipt of adjuvant radiotherapy in women with breast cancer. J Natl Cancer Inst 2008;100:199-206.
27. Hershman DL, Buono D, McBride RB, Tsai WY, Neugut AI. Influence of private practice setting and physician charac-teristics on the use of breast cancer adjuvant chemotherapy for elderly women. Cancer 2009;115:3848-3857
28. Panageas KS, Schrag D, Riedel E, Bach PB, Begg CB. The effect of clustering of outcomes on the association of pro-cedure volume and surgical outcomes. Ann Intern Med 2003;139:658-665.
29. Rose AJ, Backus BM, Gershman ST, Santos P, Ash AS, Bat-taglia TA. Predictors of aggressive therapy for nonmetastatic prostate carcinoma in Massachusetts from 1998 to 2002. Med Care 2007;45:440-447.
30. Pisu M, Oliver JS, Kim YI, Elder K, Martin M, Richardson LC. Treatment for older prostate cancer patients: disparities in a southern state. Med Care 2010;48:915-922.
31. Klabunde CN, Potosky AL, Legler JM, Warren JL. Devel-opment of a comorbidity index using physician claims data. J Clin Epidemiol 2000;53:1258-1267.
32. Pisu M, Richardson LC, Kim YI, et al. Less-than-standard treatment in rectal cancer patients: which patients are at risk? J Natl Med Assoc 2010;102:190-198.
33. Landrum MB, Keating NL, Lamont EB, Bozeman SR, McNeil BJ. Reasons for underuse of recommended therapies for colorectal and lung cancer in the Veterans Health Ad-ministration. Cancer 2012;118:3345-3355.
34. Neugut AI, Hillyer GC, Kushi LH, et al. Noninitiation of adjuvant chemotherapy in women with localized breast cancer: the breast cancer quality of care study. J Clin Oncol 2012;30:3800-3809.
35. Bickell NA, Weidmann J, Fei K, Lin JJ, Leventhal H. Un-deruse of breast cancer adjuvant treatment: patient knowl-edge, beliefs, and medical mistrust. J Clin Oncol 2009;27: 5160-5167.
36. Mandelblatt JS, Faul LA, Luta G, et al. Patient and physician decision styles and breast cancer chemotherapy use in older women: Cancer and Leukemia Group B protocol 369901. J Clin Oncol 2012;30:2609-2614.
37. Mandelblatt JS, Sheppard VB, Hurria A, et al. Breast cancer adjuvant chemotherapy decisions in older women: the role of patient preference and interactions with physicians. J Clin Oncol 2010;28:3146-3153.
38. Sloan JA, Goldberg RM, Sargent DJ, et al. Women experience greater toxicity with fluorouracil-based chemotherapy for colorectal cancer. J Clin Oncol 2002;20:1491-1498.
39. Stein BN, Petrelli NJ, Douglass HO, Driscoll DL, Arcangeli G, Meropol NJ. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995;75:11-17.
40. Zalcberg J, Kerr D, Seymour L, Palmer M. Haematological and non-haematological toxicity after 5-fluorouracil and leucovorin in patients with advanced colorectal cancer is significantly associated with gender, increasing age and cycle number. Tomudex International Study Group. Eur J Cancer 1998;34:1871-1875.
41. Hu CY, Delclos GL, Chan W, Du XL. Assessing the initia-tion and completion of adjuvant chemotherapy in a large nationwide and population-based cohort of elderly patients with stage-III colon cancer. Med Oncol 2011;28:1062-1074.
42. Kahn KL, Adams JL, Weeks JC, et al. Adjuvant chemother-apy use and adverse events among older patients with stage III colon cancer. JAMA 2010;303:1037-1045.
43. Etzioni DA, El-Khoueiry AB, Beart RW Jr. Rates and pre-dictors of chemotherapy use for stage III colon cancer: a systematic review. Cancer 2008;113:3279-3289.
44. Warren JL, Harlan LC, Fahey A, et al. Utility of the SEER-Medicare data to identify chemotherapy use. Med Care 2002;40(8 Suppl):IV-55-61.